Introduction
The conjugation of small ubiquitin-like modifier (SUMO) to specific lysine residues of cellular proteins is a dynamic and reversible posttranslational modification (1) . Deficiencies in SUMOylation enzymes have been reported to affect the pathogenesis and severity of inflammatory diseases (2) (3) (4) . Transcription factors are major SUMOylation substrates (5) , and SUMOylation-regulated transcription factors are involved in the pathogenesis of type 1 diabetes (T1D) (6, 7) . However, it is not known whether T cell-restricted SUMOylation based on a single transcription factor modulates autoimmune diabetes, and if so, what mechanism is involved.
Autoimmune diabetes is a T cell-mediated inflammatory disease caused by the destruction of insulin-producing β cells. Studies in animal models of spontaneous autoimmune diabetes, particularly in NOD mice, have demonstrated that disease pathogenesis depends on the effector function of islet antigen-specific CD4 + and CD8 + T cells (8) . IL-21, produced mainly by activated CD4 + T cells, is critical for enhancing the effector functions of CD8 + T cells (9) . Moreover, systemic deletion of IL-21 or its receptor renders NOD mice resistant to diabetes, while β cell-specific overexpression of IL-21 elicits diabetes in diabetes-resistant C57BL/6 mice (10) (11) (12) . Importantly, memory CD4 + T cells from patients with T1D have been reported to express high levels of IL-21 and surface molecules associated with follicular helper T (Tfh) cells (13, 14) , further supporting the concept that IL-21-producing Tfh cells play a crucial role in the pathogenesis of T1D. The transcription factor c-Maf was previously reported to be a Th2 cell-specific factor that transactivates the Il4 gene (15) . However, expression of transgenic c-Maf in NOD T cells has a minimal enhancing effect on IL-4 expression and does not protect NOD mice from autoimmune diabetes (16) . Subsequent studies have revealed that SUMOylation at the lysine 33 residue reduces the ability of c-Maf to bind the Il4 promoter and decreases its transactivating activity in a luciferase reporter assay (7, 17) . Moreover, an association of c-Maf SUMOylation with autoimmune diabetogenesis has been suggested, because the level of SUMOylated c-Maf in CD4 + T cells is significantly higher in NOD mice than in diabetes-resistant B10.D2 mice (7) . In addition, recent reports indicated that c-Maf binds directly to the Il21 promoter in CD4 + T cells (18) and is critical for the development of Th17 and Tfh cells (19) . Furthermore, a subset of IL-21
+ T cells with a Tfh-like phenotype and containing abundant c-Maf contributed to CD8 + T cell-dependent diabetes progression in NOD mice (20) . However, the effect of c-Maf SUMOylation on IL-21 production and the development of disease in NOD mice is not well defined. In this study, we used transgenic NOD mice overexpressing wild-type c-Maf (Tg-WTc) or K33R c-Maf, which has a mutated SUMOylation site (Tg-KRc), to demonstrate that the SUMOylation status of c-Maf possesses a stronger effect than its level of expression on the SUMOylation is involved in the development of several inflammatory diseases, but the physiological significance of SUMOmodulated c-Maf in autoimmune diabetes is not completely understood. Here, we report that an age-dependent attenuation of c-Maf SUMOylation in CD4 + T cells is positively correlated with the IL-21-mediated diabetogenesis in NOD mice. Using 2 strains of T cell-specific transgenic NOD mice overexpressing wild-type c-Maf (Tg-WTc) or SUMOylation site-mutated c-Maf (Tg-KRc), we demonstrated that Tg-KRc mice developed diabetes more rapidly than Tg-WTc mice in a CD4 + T cell-autonomous manner. Moreover, SUMO-defective c-Maf preferentially transactivated Il21 to promote the development of CD4 + T cells with an extrafollicular helper T cell phenotype and expand the numbers of granzyme B-producing effector/memory CD8 + T cells. Furthermore, SUMO-defective c-Maf selectively inhibited recruitment of Daxx/HDAC2 to the Il21 promoter and enhanced histone acetylation mediated by CREB-binding protein (CBP) and p300. Using pharmacological interference with CBP/p300, we illustrated that CBP30 treatment ameliorated c-Maf-mediated/IL-21-based diabetogenesis. Taken together, our results show that the SUMOylation status of c-Maf has a stronger regulatory effect on IL-21 than the level of c-Maf expression, through an epigenetic mechanism. These findings provide new insights into how SUMOylation modulates the pathogenesis of autoimmune diabetes in a T cell-restricted manner and on the basis of a single transcription factor. and Huey-Kang Sytwu dent attenuation of c-Maf SUMOylation underlies the development of autoimmune diabetes in NOD mice. It has been reported that c-Maf is critical for transactivating Il4 (15) , Il10 (21) , and Il21 (18) . We examined the expression of IL-4, IL-10, and IL-21 in CD4 + T cells of NOD mice at different ages. Our results revealed that expressions of IL-21 mRNA and protein were significantly higher in 12-to 14-week-old NOD CD4 + T cells than in 6-to 8-week-old NOD CD4 + T cells, whereas expressions of IL-4 or IL-10 mRNA and protein were indistinguishable between the 2 groups ( Figure 1 , C and D, respectively), suggesting that IL-21 production in CD4 + T cells of NOD mice was positively correlated with diabetogenesis. Since c-Maf transactivates Il4, Il10, and Il21 through a direct interaction with the c-Maf response element (MARE) motif in these promoters (15, 18, 21) , we next performed a ChIP assay to examine whether the SUMOylation status of c-Maf affects its interaction with the MARE motifs in these promoters. Our results indicated that the binding of c-Maf was not detected in the regions devoid of c-Maf response element (non-MARE) of the Il4 promoter (Il4p), the Il10 promoter (Il10p), or the Il21 promoter (Il21p) of NOD CD4 + T cells ( Figure 1E and Supplemental Figure 1 , B and C, respectively). Moreover, we observed that c-Maf enrichment in the Il21p MARE was significantly greater in 12-to 14-week-old NOD CD4 + T cells than in 6-to 8-week-old NOD CD4 + T cells ( Figure 1E ), whereas c-Maf enrichment in the Il4p MARE or the Il10p MARE was comparable in both groups (Supplemental Figure 1 , B and C, respectively). These findings suggested that c-Maf is recruited more efficiently to the Il21p than to the Il4p or to the Il10p in 12-to 14-week-old NOD CD4 + T cells and that this age-dependent increase in the Il21p recruitment is negatively correlated with the level of c-Maf SUMOylation.
SUMO-defective c-Maf preferentially transactivates
To evaluate whether pharmacological intervention in the SUMOylation process affects c-Maf-modulated IL-21 production, we treated CD4 + T cells with anacardic acid, which is reported as a SUMOylation inhibitor (22) . Our results indicated that the amount of SUMOylated c-Maf was significantly decreased in anacardic acid-treated CD4 + T cells compared with that in solvent-treated cells, whereas the amount of unSUMOylated c-Maf was comparable (Figure 1F and Supplemental Table 1C ). Notably, we observed that levels of IL-21 mRNA and protein were significantly higher in anacardic acid-treated CD4 + T cells than in solvent-treated cells, whereas levels of IL-4 or IL-10 mRNA and protein were indistinguishable between these 2 groups of CD4 + T cells ( Figure 1 , G and H, respectively). Moreover, a ChIP assay revealed that c-Maf enrichment in the Il21p MARE was significantly higher in anacardic acid-treated CD4 + T cells than in solvent-treated cells ( Figure 1I ), whereas c-Maf enrichment in the Il4p MARE or the Il10p MARE was comparable in the 2 groups (Supplemental Figure 1 , D and E, respectively). This indicated that pharmacological downregulation of c-Maf SUMOylation preferentially promotes its transactivation of Il21 in NOD CD4 + T cells. Besides, we observed that the level of IL-21 mRNA was significantly higher in anacardic acid-treated B6 CD4 + T cells than in solvent-treated B6 CD4 + T cells (Supplemental Figure 1F) , suggesting that anacardic acid has a similar effect of promoting IL-21 expression of CD4 + T cells from non-diabetes-prone mice. Taken together, our results suggest that an age-dependent attenuation of c-Maf SUMOylation in CD4 + T cells is positively correlated with an IL-21-mediated diabetogenic process in NOD mice.
initiation and early development of autoimmune diabetes. These experiments provide new insights into the underlying mechanisms linking the SUMOylation status of a single transcription factor with the pathogenesis of autoimmune diabetes.
Results

c-Maf SUMOylation in CD4
+ T cells is inversely correlated with the severity of insulitis and IL-21 production in NOD mice. Recent studies have shown that deficiencies in SUMOylation enzymes have significant impacts on the pathogenesis and severity of inflammatory diseases (2) (3) (4) . However, the physiological significance and detailed mechanism(s) by which SUMOylation modulates autoimmune diabetes are not completely understood. Since the SUMOylation-regulated transcription factor c-Maf has been reported to be associated with the pathogenesis of autoimmune diabetes (7), we first determined the SUMOylation status of c-Maf in CD4 + T cells of NOD mice at different stages of diabetogenesis. We activated CD4
+ T cells from 6-to 8-week-old and 12-to 14-week-old NOD mice in vitro using anti-CD3 and anti-CD28 for 36 hours, then immunoprecipitated cell lysates with anti-c-Maf followed by Western blotting with anti-SUMO-1 or anti-c-Maf. In these samples, in addition to the typical c-Maf species (~50 kDa), a higher-molecular mass species (~70 kDa) was detected ( Figure  1A) , consistent with the previously reported size of SUMOylated c-Maf (7, 17) . Notably, the amount of SUMOylated c-Maf in CD4 + T cells was at least 50% lower in 12-to 14-week-old mice than in 6-to 8-week-old mice, whereas the amount of unSUMOylated c-Maf was comparable (Figure 1A and Supplemental Table 1A ; supplemental material available online with this article; https:// doi.org/10.1172/JCI98786DS1), suggesting an inverse correlation between c-Maf SUMOylation and the severity of insulitis in NOD mice. Since c-Maf SUMOylation was catalyzed by a specific enzyme cascade, including SAE1/SAE2 (SUMO E1 activating enzymes), UBC9 (a SUMO E2 conjugating enzyme), and PIAS1 (a SUMO E3 ligase) (1, 5, 7, 17) , we next examined the expression of SUMOylation enzymes in NOD CD4 + T cells from mice of different ages. Our results demonstrated that the transcript levels of Sae1, Sae2, Ubc9, and Pias1 in CD4 + T cells were significantly lower in 12-to 14-week-old mice than in 6-to 8-week-old mice ( Figure  1B ), implying that downregulation of the c-Maf-associated SUMO enzymatic cascade in CD4 + T cells was positively associated with the diabetogenic process and its severity in NOD mice. Besides, we observed that the amount of SUMOylated or unSUMO ylated c-Maf in CD4 + T cells was comparable between 6-to 8-week-old C57BL/6 (B6) and NOD mice (Supplemental Figure 1A) , suggesting that the SUMOylation status of c-Maf in CD4 + T cells from 6-to 8-week-old mice was similar in both non-diabetes-prone and spontaneous diabetic mouse strains. However, the ratio of SUMOylated to unSUMOylated c-Maf was significantly decreased by approximately 50% in 12-to 14-week-old NOD CD4 + T cells compared with that in 6-to 8-week-old NOD CD4 + T cells, whereas this SUMOylated/unSUMOylated ratio was comparable between 6-to 8-week-old and 12-to 14-week-old B6 CD4 + T cells (Supplemental Figure 1A and Supplemental + cells cultured for 36 hours as described in F. For E and I, isotype-matched IgG was used as a control. See complete unedited blots in the supplemental material. Data represent the mean ± SEM; n = 5 mice (A and F), n = 3 mice (B-E and G-I) per group; 3 independent experiments. *P < 0.05; **P < 0.01; 2-tailed Student's t test (A-D and F-H) or 1-way ANOVA with Tukey's post-test (E and I). 
CD4
+ plus CD8 + T cells from 12-to 14-week-old indicated NOD mice were transferred into NOD.Rag1
-/-mice; all groups were treated simultaneously in 2 independent experiments. The control CD4/control CD8 (white circles) group is presented in both I and J. Diabetic incidences among groups that received control CD8 + T cells plus different CD4 + T cells (I) and diabetic incidences in among groups that received control CD4 + T cells plus different CD8 + T cells (J) were compared with each other by a log-rank test. See complete unedited blots in the supplemental material. For E, data represent the mean ± SEM; n = 3 mice (B and C) or n = 5 mice (D and E) per group; 3 independent experiments (B-E) or 2 independent experiments (H). *P < 0.05; **P < 0.01; 1-way ANOVA with Tukey's post-test (E) or log-rank test (F-J). Figure 2I ); the latter group developed diabetes at a rate that was indistinguishable from that in recipients of control CD4 + cells plus transgenic CD8 + cells ( Figure  2J ). This result further indicates that the SUMO-defective c-Mafmediated acceleration of diabetes development in Tg-KRc mice is CD4 + T cell autonomous. Taken together, our results provide in vivo evidence that the SUMOylation status of c-Maf is more critical than its level of expression for the initiation and early development of disease in NOD mice, implying the effect of SUMO-defective c-Maf on the pathogenesis of autoimmune diabetes.
To investigate whether transgenic SUMO-defective c-Maf accelerates diabetic kinetics by modulating the development of peripheral CD4
+ T cells, we first determined the numbers of CD4 + T cells in the spleens of these transgenic mice and observed that the number of splenic CD4 + T cells in Tg-WTc or Tg-KRc mice was lower than that in control mice (Supplemental Figure 3A) , whereas the number of splenic CD8 + T cells was indistinguishable between Tg and control mice (Supplemental Figure 3A) , consistent with a previous report that overexpression of c-Maf in T cells resulted in a reduced CD4 + T cell number in the spleen (23) . However, the number of splenic CD4 + T cells was comparable between Tg-WTc and Tg-KRc mice (Supplemental Figure 3A) , suggesting that the SUMOylation status of c-Maf does not additionally impact on CD4 + splenocyte survival. Moreover, we observed that the frequency of splenic CD69 
Overexpression of SUMO-defective c-Maf preferentially augments the development of IL-21-producing CD4
+ T cells. It has been reported that c-Maf is required to enhance Il4 transactivation in Th2 cells (15) and to promote IL-10 and/or IL-21 expression in Th17 (19, 21) , primer P1 that locates on the distal Lck promoter and 2 reverse primers P2 and P3 specifically to recognize wild-type or K33R c-Maf cDNA at nucleotide 98 (A and G, respectively) ( Figure 2A ). The Tg-WTc and Tg-KRc mice can thus be distinguished by PCR genotyping with primers P1/P2 or P1/P3, respectively ( Figure  2B ). Western blot analysis indicated that expression of c-Maf in Tg-WTc and Tg-KRc CD4 + cells was much higher than that in control CD4
+ cells and was similar in both transgenic lines ( Figure 2C ). To examine whether K33R c-Maf in CD4 + T cells was able to resist SUMO modification, we prepared cell lysates in the presence of the deSUMO ylation inhibitor NEM from NOD CD4 + T cells stimulated with anti-CD3/CD28, and immunoprecipitated them with anti-HA followed by anti-SUMO-1 or anti-HA blotting. The SUMOylated form of transgenic c-Maf was detected in Tg-WTc cells but was barely detectable in Tg-KRc cells ( Figure 2D ), demonstrating that transgenic K33R c-Maf is resistant to SUMOylation in vivo.
In addition, the results of immunoprecipitation with anti-cMaf followed by blotting with anti-SUMO-1 or anti-c-Maf demonstrated that the amounts of both SUMOylated and unSUMOylated c-Maf were augmented in Tg-WTc CD4 + T cells compared with control cells ( Figure 2E and Supplemental Table 2 ). However, the ratio of SUMOylated to unSUMOylated c-Maf in Tg-WTc CD4 2E and Supplemental Table 2 ), the ratio of SUMOylated to unSUMOylated c-Maf was significantly decreased by approximately 50% in Tg-KRc CD4 + T cells compared with control cells ( Figure 2E ). This unique "low ratio" of SUMOylated/unSUMOylated c-Maf in Tg-KRc CD4 + T cells may physiologically mimic the SUMOylation status of c-Maf in CD4 + T cells of 12-to 14-week-old NOD mice, providing a feasible and available model to explore the modulatory role of c-Maf SUMOylation in the diabetogenic process in NOD mice.
Accelerated kinetics of autoimmune diabetes in SUMO-defective c-Maf-transgenic NOD mice. To investigate whether the SUMOylation status of c-Maf in CD4
+ T cells modulates the pathogenesis of autoimmune diabetes in NOD mice, we first compared the disease kinetics and severity in c-Maf-transgenic mice and their littermate controls. The diabetes kinetics and incidence in Tg-WTc and control mice were indistinguishable, indicating that overexpression of wild-type c-Maf in T cells does not influence the progress and severity of diabetes in NOD mice ( Figure 2F ). In contrast, Tg-KRc mice showed accelerated development of diabetes before 13 weeks of age compared with control mice (30% vs. 4%, P = 0.0236; Supplemental Figure 2A ). At 18 weeks of age, the incidence of diabetes in Tg-KRc mice reached 90%, but in control mice was 37% (P = 0.0001; Supplemental Figure 2B ). Although the overall diabetic rate at 40 weeks of age was similar in Tg-WTc and Tg-KRc mice, the diabetic kinetics in Tg-KRc mice was significantly faster than that of control mice (P = 0.005; Figure 2G ), implying that c-Maf SUMOylation may negatively modulate the initial stages of the develop-jci. Figure 4A) . Moreover, we observed that overexpression of SUMO-defective c-Maf, but + T cells cultured for 36 hours as described in E. Isotype-matched IgG was used as a control. Data represent the mean ± SEM; n = 6 mice (A and B), n = 10 mice (C and D), n = 3 mice (E-G), or n = 5 mice (H and I) per group; 3-4 independent experiments. *P < 0.05; **P < 0.01; 1-way ANOVA with Tukey's post-test (A, C, E, and G-I) or 2-tailed Student's t test (B and D). Figure 5I) . Moreover, the level of IL-21 mRNA was significantly higher in B6.Tg-KRc CD4 + T cells than in B6.Tg-WTc CD4 + T cells (Supplemental Figure 5I) , suggesting that SUMO-defective c-Maf is able to augment IL-21 expression in CD4 + T cells regardless of the susceptibility of mouse strains to autoimmune diabetes. Taken together, these results suggest that the SUMOylation status of c-Maf has a stronger effect than its level of expression on transactivation of Il21 and that this phenomenon is more marked for Il21 than for Il4 and Il10 in NOD CD4 + T cells.
SUMO-defective c-Maf promotes differentiation of CD4
+ T cells with an extrafollicular helper T cell phenotype. It has been reported that IL-21 is critical for the generation of Tfh cells (26, 27) and that impaired production of this cytokine limits the development of Tfh cells in c-Maf-deficient mice after immunization (19) . + T cell population. Tfh cells are typically characterized by CXCR5 expression, which enables them to migrate to B cell follicles and reside within germinal centers (28, 29) . Recently, a distinct subset of IL-21-producing extrafollicular helper T (Tefh) cells, which was classified by high expression of ICOS and/or PD-1 but lacked CXCR5, was identified and contributed to pathogenesis in mouse models of autoimmune or autoimmune-like diseases (20, (30) (31) (32) . We observed that the frequency of splenic Tfh cells (CXCR5 Figure 5D , bottom panel). These in vitro data supported that augmented IL-21 production by Tg-KRc CD4 + T cells enhanced more granzyme B expression in CD8 + T cells, compared with that of Tg-WTc CD4 + T cells. It has been reported that IL-21/IL-21R signaling in CD8 + T cells is critical for the development of autoimmune diabetes in NOD mice (20) . To characterize the impact of IL-21R signaling on KLRG1 + CD8 + splenocytes were indistinguishable between control and Tg mice ( Figure 5A ), implying that neither wild-type nor SUMO-defective c-Maf affects the activation status or short-lived effector population of CD8 + T cells in NOD mice. Interestingly, we observed that the level of Cd44 transcripts was enhanced in Tg-KRc CD8 + T cells compared with Tg-WTc CD8 + T cells (Supplemental Figure 4B ) and the population of splenic CD44 hi CD8 + T cells was significantly higher in Tg-KRc mice than in control and Tg-WTc mice ( Figure 5A ), suggesting that SUMO-defective c-Maf expands effector/memory CD8 + T cells in Tg-KRc mice; this is consistent with a previous report that overexpression of IL-21 promotes CD44 hi CD8
SUMO-defective c-Maf expands effector/memory CD8 + T cells and enhances their granzyme B production and diabetogenic activity in an
+ T cell accumulation (33) . We further determined the steady-state expression of cytotoxic T lymphocyte-related genes and observed that the level of Gzmb transcripts in CD8 + T cells was significantly increased in Tg-KRc mice compared with control and Tg-WTc mice, whereas the levels of Ifng and Prf1 transcripts were comparable in all strains ( Figure 5B) . Moreover, in all mice, Gzmb was more strongly expressed in CD44 hi CD8
+ T cells compared with CD44 lo CD8
+ T cells ( Figure 5C ). Furthermore, the expression level of granzyme B protein in CD8 + T cells was remarkably T cells (Supplemental Figure 6C) −/− recipients reconstituted as described in F. Data represent the mean ± SEM; n = 6 mice (A), n = 4 mice (B-D), n = 3 mice (G) per group; 3 independent experiments (A-D) or 2 independent experiments (F and G). *P < 0.05; **P < 0.01; 1-way ANOVA with Tukey's post-test (A, B, D, and G) , 2-tailed Student's t test (C), or log-rank test (E and F).
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jci.org Volume 128 Number 9 September 2018 of these transcripts were significantly decreased following IL-21.Fc administration ( Figure 5G ). Moreover, we observed that the expression levels of CD44 or granzyme B mRNA and protein in CD8 + T cells were significantly decreased on day 14 and day 28 in IL-21. Fc-treated groups, compared with those on day 14 in control.Fctreated groups, respectively (Supplemental Figure 6 , D-G, respectively). Moreover, the expression levels of CD44 or granzyme B in CD8 + T cells on day 14 and day 28 were comparable in IL-21R.Fctreated groups (Supplemental Figure 6, D-G, respectively) . However, the expression levels of CD44 or granzyme B in CD8 + T cells on day 42 in IL-21R.Fc-treated groups were significantly increased, compared with those on day 14 and day 28, and were similar to those on day 14 in control.Fc-treated groups (Supplemental Figure   NOD .Rag1 -/-mice that received Tg-KRc CD4 + and control CD8 + T cells developed diabetes more rapidly than mice that received Tg-WTc CD4 + and control CD8 + T cells ( Figure 5F and Supplemental Table 3 ). In contrast, diabetic development in the IL-21R. Fc-treated groups, which was attenuated compared with that in the control.Fc-treated groups, was comparable in recipients of Tg-WTc CD4 + /control CD8 + or Tg-KRc CD4 + /control CD8 + T cells ( Figure  5F and Supplemental Table 3 suggested a SUMO-defective c-Maf-associated enhancement of histone acetylation in the Il21p. Since HATs such as CREB-binding protein (CBP) or p300 can directly interact with c-Maf and enhance its transactivation on crystallin genes (38), we evaluated the recruitment of CBP and p300 to the Il4p and the Il21p. Our results revealed that the levels of CBP and p300 binding to the Il4p MARE were both increased in Tg-WTc and Tg-KRc CD4 + T cells compared with control cells, but were comparable between Tg-WTc and Tg-KRc cells (Figure 6, F and G, respectively) , suggesting that the SUMOylation status of c-Maf has a minimal effect on modulation of CBP/p300 recruitment to the Il4p. However, CBP and p300 recruitment to the Il21p significantly increased in a stepwise fashion from control to Tg-WTc to Tg-KRc CD4 + T cells (Figure 6, F and G, respectively) . These results suggested that SUMO-defective c-Maf may augment CBP/p300 recruitment and subsequently enhance histone acetylation in the Il21p of Tg-KRc CD4 + T cells. Besides, we observed that the acetylation levels of both H3 and H4 in the Il21p MARE were significantly higher in 12-to 14-week-old NOD CD4 + T cells compared with 12-to 14-weekold B6 CD4 + T cells, whereas they were comparable between 6-to 8-week-old B6 and NOD CD4 + T cells (Supplemental Figure 7 , A and B, respectively). The finding of an age-associated increase of histone acetylation in NOD CD4 + T cells supported the idea that enhanced histone acetylation was inversely correlated with the attenuation of c-Maf SUMOylation and was involved in the pathogenesis of autoimmune diabetes. Taken together, our results provide an interesting clue that SUMO-defective c-Maf deters Daxx/ HDAC2 recruitment to the Il21p and promotes CBP/p300-mediated histone acetylation, implying the existence of a c-Maf SUMOylation-based epigenetic regulation of the Il21p.
A CBP/p300 inhibitor attenuates SUMO-defective c-Maf-mediated transactivation of Il21 and ameliorates autoimmune diabetes in NOD mice. To evaluate whether pharmacological targeting of CBP/p300 affects SUMO-defective c-Maf-mediated transactivation of Il21 in CD4 + T cells, we treated these T cells with CBP30, which has been reported to inhibit CBP/p300 via specifically binding to their bromodomains (39) . Our results revealed markedly reduced levels of Il21 transcripts in CBP30-treated control, Tg-WTc, or Tg-KRc cells, compared with the respective solvent-treated groups ( Figure 7A) . Moreover, the levels of c-Maf binding to the Il21p were significantly decreased in the CBP30-treated groups compared with solvent-treated groups ( Figure 7B ), indicating that CBP30 inhibits c-Maf-mediated transactivation of Il21 in NOD CD4 + T cells. Furthermore, we observed that CBP/p300 recruitment to the Il21p was much lower in CBP30-treated groups than in solvent-treated groups ( Figure  7 , C and D, respectively), whereas the acetylation levels of both histones H3 and H4 in the Il21p were significantly decreased in CBP30-treated groups compared with solvent-treated groups ( Figure 7 , E and F, respectively). These results suggest that CBP30 attenuates c-Maf-mediated transactivation of Il21 by downregulating CBP/p300-mediated histone acetylation in NOD CD4 + T cells. To evaluate whether CBP30 has the potential to modulate SUMO-defective c-Maf-mediated diabetogenesis in vivo, we cotransferred effector CD4 + T cells (CD4 + CD25 -) from transgenic mice with control CD8 + T cells into NOD.Rag1 -/-mice that were then treated with CBP30. Our results indicated that after solvent 6, D-G, respectively). These results provide evidence that the suppressive effect of the IL-21R.Fc treatment on the activation status of CD8 + T cells was sustained for up to 14 days and was abolished at 28 days after the final administration. Taken together, these results indicate an IL-21-dependent promotion of CD44 and granzyme B expression in CD8 + T cells in vivo and further support the hypothesis that SUMO-defective c-Maf regulates the CD4/IL-21/CD8 axis to accelerate the pathogenesis of diabetes in Tg-KRc mice.
SUMO-defective c-Maf prevents Daxx/HDAC2 recruitment to the Il21p and enhances CBP/p300-mediated histone acetylation. It has been reported that SUMOylation of transcription factors triggers the recruitment of corepressors, such as death domain-associated protein 6 (Daxx), to suppress gene expression (34, 35) . To investigate whether the SUMOylation status of c-Maf is involved in Daxx recruitment to the MARE motif, we performed a ChIP assay and observed that Daxx was detected on the Il4p MARE and the Il21p MARE in control, Tg-WTc, and Tg-KRc CD4 + T cells ( Figure 6A (36) and HDAC2 (35), we next evaluated whether HDAC(s) were recruited to the MARE motif. Our results revealed that both HDAC1 and HDAC2 were detected on the MARE motifs in the Il4p and the Il21p (Figure 6 , B and C, respectively), implying that HDAC1 and HDAC2 are involved in Daxx-associated transcriptional repression of c-Maf-targeted promoters. We observed that HDAC1 enrichment to both the Il4p and the Il21p was comparable in CD4 + T cells from control and the 2 transgenic mouse lines ( Figure 6B ), suggesting that the recruitment of HDAC1 to these motifs is independent of the amount or degree of SUMOylation of c-Maf. Interestingly, similarly to that of Daxx, the level of HDAC2 recruitment to the Il21p was markedly increased in comparison with control cells in Tg-WTc cells but not in Tg-KRc cells, whereas its recruitment to the Il4p was similar in all cells ( Figure 6C ). These results imply that HDAC2 is involved in the formation of a Daxx-associated repression complex on the Il21p that is initiated in a dose-dependent manner by c-Maf SUMOylation. The acetylation of histones, counterregulated by histone acetyltransferases (HATs) and HDACs, is usually associated with open chromatin and active promoters that enable transcription factors to interact with target sequences (37) . We next analyzed the extent of acetylation of histone H3 (H3ac) and H4 (H4ac) on the MARE motifs. Our results revealed that the acetylation level of both H3 and H4 in the Il21p was significantly higher in Tg-KRc cells than in control and Tg-WTc cells, whereas their acetylation levels in the Il4p were indistinguishable in all cells (Figure 6, D and E, respectively) . This jci.org Volume 128 Number 9 September 2018
and protein in CD8 + T cells were significantly decreased on day 14, day 28, and day 42 in CBP30-treated groups, compared with those on day 14 in solvent-treated groups (Supplemental Figure  8, A-D) , suggesting that the impairment of the c-Maf-mediated IL-21/granzyme B signaling axis by CBP30 was sustained up to 28 days after the end of treatment. These results indicated that CBP30 markedly impairs the c-Maf-mediated IL-21/granzyme signaling axis in vivo and may protect NOD mice from autoimmune diabetes. Taken together, our results provide the new insight that pharmacological intervention targeting CBP/p300 is a possible therapeutic strategy to ameliorate the c-Maf-mediated/ IL-21-based pathogenesis of autoimmune diabetes.
treatment, NOD.Rag1
-/-mice that received Tg-KRc CD4 + /control CD8 + cells developed diabetes more rapidly than mice that received Tg-WTc CD4 + /control CD8 + cells ( Figure 7G and Supplemental Table 4 ). Strikingly, the onset of diabetes was significantly delayed and its incidence was lower in CBP30-treated mice that received either Tg-WTc CD4 + /control CD8 + or Tg-KRc CD4 + / control CD8 + cells than in solvent-treated mice ( Figure 7G and Supplemental Table 4 ). Moreover, the levels of transcripts of Il21 in CD4 + cells and Gzmb in CD8 + cells were significantly reduced in CBP30-treated mice compared with solvent-treated mice (Figure 7H) . Furthermore, we observed that the expression levels of IL-21 mRNA and protein in CD4 + T cells and granzyme B mRNA (ROS) are the key regulators that control the SUMO-deSUMOylation equilibrium in cells (40) . Hydrogen peroxide-induced (H 2 O 2 -induced) ROS attenuated SUMOylation by interfering with the formation of disulfide bonds in SUMO E1 and E2 (41) . Moreover, a high concentration of ROS impaired T cell receptor-driven Myc upregulation in CD4 + T cells (42) . Myc has been reported to be a master regulator of the SUMOylation system, which acts by inducing transcription of the genes of the SUMO enzymatic cascades (43) . These results suggest that the levels of ROS may inversely correlate with the SUMOylation status of proteins in CD4 + T cells. A recent study demonstrated that both exogenous and endogenous sources of ROS are involved in initiating cytokine responses of CD4 + T cells (44) . The loss of ROS synthesis significantly alters the effector function of T cells and ameliorates autoimmune diabetes in NOD mice (45) . Interestingly, we also observed that the level of ROS in CD4 + T cells was moderately higher in 12-to 14-week-old mice than in 6-to 8-week-old mice (data not shown), suggesting that an age-dependent upregulation of ROS may impair the expression and function of SUMO enzymes and thereby attenuate c-Maf SUMOylation in NOD CD4 + T cells, resulting in an increased pathogenic effector function.
A previous report has revealed that any single-lysine mutation (K to R) of c-Maf was not able to prevent its ubiquitination,
In this study, we demonstrated that the SUMOylation status of c-Maf possessed a stronger effect than its level of expression on the initiation and early development of autoimmune diabetes in NOD mice. This unique process promotes the differentiation of CD4 + T cells toward a Tefh cell phenotype and expands the numbers of granzyme B-producing effector/memory CD8 + T cells to accelerate the onset of diabetes in an IL-21-dependent manner. Furthermore, SUMO-defective c-Maf selectively deterred recruitment of Daxx/HDAC2 to the Il21p and enhanced CBP/p300-mediated histone acetylation, revealing a mechanism of c-Maf SUMOylation-based epigenetic regulation in NOD mice ( Figure  8 ). These findings provide new insights into the underlying mechanisms linking the SUMOylation status of a single transcription factor with the pathogenesis of autoimmune diabetes.
Discussion
Global deficiencies in SUMOylation enzymes such as UBC9 and PIAS1 have been reported to impact significantly on the pathogenesis and severity of inflammatory diseases (2, 3) . Accumulating evidence also indicates that selective deletion of Ubc9 within Tregs results in fatal early-onset autoimmunity (4). These reports indicated the physiological significance of SUMOylation in inflammatory diseases. It has been reported that reactive oxygen species -/-mice, and Il21r -/-mice were originally purchased from The Jackson Laboratory. C57BL/6 mice were obtained from the National Laboratory Animal Center, Taipei, Taiwan. Il21r -/-mice were backcrossed to the NOD strain for 5 generations. The protocol to generate transgenic mice was as described previously (53) . Briefly, HA-tagged mouse wild-type c-Maf or K33R c-Maf cDNA, a gift from Shi-Chuen Miaw (College of Medicine, National Taiwan University, Taipei, Taiwan), was subcloned into the distal Lck promoter expression vector to generate the dLck-HA-WTc or dLck-HA-KRc constructs. The linearized DNA fragment was purified and microinjected into the pronuclei of 1-cell NOD embryos. These injected embryos were then implanted into pseudopregnant (BALB/c × FVB) F 1 females. Tg-WTc and Tg-KRc NOD mice were backcrossed to the C57BL/6 strain for 6 generations. All mice were bred in the specific pathogen-free facility of the animal center at the National Defense Medical Center (Taipei, Taiwan).
Statistics. The log-rank (Mantel-Cox) test was used for the comparison of survival curves. A 2-tailed Student's unpaired t test was used for comparisons between 2 groups, and 1-way ANOVA with Tukey's post-test was used for multigroup comparisons. A P value less than 0.05 was considered significant.
Study approval. All protocols using live animals were carried out in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee at the National Defense Medical Center.
Additional methods can be found in Supplemental Methods, available online.
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suggesting that ubiquitination of this transcription factor was mediated by multiple lysine residues (46) . Subsequent studies demonstrated that polyubiquitination of c-Maf was mediated by the ubiquitin-conjugating enzyme UBE2O (47) and the ubiquitin ligase HERC4 (48) . UBE2O mediated ubiquitination at K331 and K345 of c-Maf (47) , and HERC4 modulated ubiquitination at K85 and K297 of c-Maf (48) . Moreover, the study of Xu et al. indicated that UBE2O-mediated c-Maf polyubiquitination was comparable between wild-type c-Maf and K33/34R c-Maf (47) . Together, these results suggest that the mutation of K33 residue alone in c-Maf is less likely to affect its ubiquitination.
Previous results from Pauza and colleagues demonstrated that transgenic expression of c-Maf controlled by a modified Cd4 promoter, which allowed its expression in both CD4 + and CD8 + T cells, had minimal effect on the development of autoimmune diabetes in NOD mice (16) . However, this modified CD4 promoter has been reported to drive transgene expression at a very early stage of thymocyte development and may potentially affect the maturation and selection of autoreactive T cells (49) . To avoid this possible influence, we generated c-Maf-transgenic mice in which expression was driven by the distal Lck promoter, which allows transgene expression from the late stages of thymocyte development (50) . Nonetheless, similarly to previous reports, our data from these Tg-WTc mice revealed that overexpression of wild-type c-Maf in T cells does not influence the progress and severity of diabetes in NOD mice. This indicates that transgenic c-Maf-mediated modulation of autoimmune diabetes in NOD mice is very limited and is independent of the stage at which it is expressed and its quantity. In contrast, the results from our Tg-KRc mice provided in vivo evidence that, compared with a quantitative increase of c-Maf in CD4 + T cells, the SUMOylation status of this transcriptional factor has a much greater effect on the initiation and early development of autoimmune diabetes in NOD mice.
Previous studies reported that memory CD4 + T cells from T1D patients express high levels of IL-21 (13, 14) , consistent with the observation that NOD mice deficient in IL-21 completely resist diabetic development (12) . These results support a critical role of IL-21 in the pathogenesis of T1D. However, there is no direct evidence to support that c-Maf SUMOylation-modulated IL-21 expression is involved in the pathogenesis of human autoimmune diabetes. Whether the pathogenic mechanism of c-Maf SUMOylation-regulated IL-21 expression elaborated in the NOD mouse model is similar in human T1D patients needs to be further explored.
It has been reported that genetic deletion of granzyme B did not confer resistance to the development of spontaneous diabetes in NOD mice (51, 52) . Kawakami and colleagues had observed that the levels of Gzma and Fas transcripts were significantly increased in the islets of NOD.Gzmb -/-mice compared with those of NOD mice (52) , suggesting that deficiency of granzyme B may result in upregulations of other cytolytic molecules, such as granzyme A and Fas, to induce β cell apoptosis in NOD.Gzmb -/-mice. In our results, other than granzyme B, we observed that the transcript of Tnfa, one of the key inflammatory cytokine genes in NOD mice, was enhanced in Tg-KRc CD8 + T cells compared with Tg-WTc CD8 + T cells (Supplemental Figure 4B) . Moreover, the transcripts of proinflammatory or inflammatory cytokine receptor genes, such as Il1r1, Il7ra, Il12rb1, Il15r, and Il18r, were also upregulated in Tg-KRc CD8 + T cells (Supplemental Figure 4B) . These results suggested that oth-
